Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world.

Akihiro TamoriKazuaki InoueTatehiro KagawaKoichi TakaguchiKazuhiro NousoYoshiaki IwasakiMasahito MinamiHoang HaiMasaru EnomotoNorifumi Kawada

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)

Glecaprevir + pibrentasvir had a remarkable anti-HCV effect in GT-1 and GT-2 patients, but not in GT-3b patients. Although this therapy was reasonably safe, it is necessary to carefully consider elderly and dropout patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
hepatitis c virus
middle aged
human immunodeficiency virus